Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ICI176, 334-1 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Active 1 | EXPERIMENTAL | 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet |
| Active 2 | EXPERIMENTAL | 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet |
| Active 3 | EXPERIMENTAL | 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet |
| Active 4 | EXPERIMENTAL | 12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet |
| Name | Type | Description |
|---|---|---|
| ICI176,334-1 | DRUG | Subject will receive single dose of ICI176,334-1 |
| Casodex 80 mg tablet | DRUG | Subject will receive single dose of Casodex 80 mg tablet |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures * Japanese healthy male subjects aged 20 to 45 years * Male subjects should be willing to use barrier contraception ie, condoms, until 3 months after the last dose of investigational...
ICI176,334-1 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development. The completed trials focused on bioequivalence and oral mucosal absorption in healthy Japanese male subjects.
ICI176,334-1 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting early-stage clinical research on this small molecule.
ICI176,334-1 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both involving healthy volunteers.
ICI176,334-1 has been studied in two completed Phase 1 trials: NCT01415778, a bioequivalence study in 48 Japanese healthy male subjects, and NCT01415791, an oral mucosal absorption study in 8 subjects. Both trials enrolled healthy male volunteers aged 20 years and older.
No alternative names for ICI176,334-1 have been disclosed. The drug is identified solely by its code name ICI176,334-1 in clinical trial records and development documentation.